Cell free tumor DNA detection market to hit $5.64 billion by 2030

The cell free tumor DNA detection market is projected to grow from $2.58 billion in 2025 to $5.64 billion by 2030, driven by rising cancer rates, non-invasive testing demand and advances in precision medicine. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Cell free tumor DNA detection gives clinicians a non-invasive way to detect and monitor cancer through blood-based testing. - The market’s growth reflects broader adoption of precision medicine, earlier cancer detection and more frequent use of molecular diagnostics. - The technology can help track treatment response, minimal residual disease and recurrence without a traditional tissue biopsy.

What happened: - The cell free tumor DNA detection market was valued at $2.58 billion in 2025. - The market is forecast to reach $3.02 billion in 2026. - The market is projected to reach $5.64 billion by 2030. - The forecast implies a 17.2% CAGR from 2025 to 2026 and a 16.9% CAGR through 2030. - The report was published by The Business Research Company on July 30, 2026.

The details: - Market growth is being supported by rising cancer incidence, breakthroughs in molecular diagnostics and wider use of PCR and NGS methods. - The market is also benefiting from growing clinical research activity and stronger preference for non-invasive testing. - Expected drivers through 2030 include precision medicine, improved ctDNA analysis technologies, AI-based diagnostic tools, higher healthcare spending in emerging markets and more early cancer detection programs. - The report points to wider liquid biopsy adoption, integration with genomic data systems, real-time tumor tracking and continued improvements in ctDNA detection technology. - The technology identifies tiny DNA fragments shed by cancer cells into the bloodstream. - The main uses are early cancer detection, treatment monitoring and tracking minimal residual disease or relapse. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - Other regions covered include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, plus updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - Personalized medicine is a major growth catalyst because it depends on detailed tumor genetics and rapid treatment adjustment. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. - That jump underscores how faster adoption of personalized medicine is increasing demand for advanced diagnostics like cell free tumor DNA testing. - The regional split suggests mature demand in North America and faster expansion potential in Asia-Pacific as healthcare spending and research scale up.

What's next: - The market is expected to keep expanding as liquid biopsy workflows become more common in clinical practice. - More use of AI, genomic data integration and earlier screening programs could deepen adoption through 2030. - Ongoing product and technology improvements are likely to push ctDNA testing further into routine cancer care. - The company is offering expert contact channels for follow-up and sales inquiries.